오름테라퓨틱

475830KOSDAQ기초 의약물질 제조업

38.3 / 100

Reference Date: 2026-07-24

Financial Score7.5 / 40

News Sentiment16.8 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Plunged 17.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Orm Therapeutics is a clinical-stage biotech company developing antibody-based targeted protein degradation (TPD²®) therapies to treat cancer. Its key candidates, ORM-5029 and ORM-1153, target HER2-positive breast cancer and hematologic malignancies, with ORM-5029 in Phase 1 trials and ORM-1153 preparing for IND submission in 2026. TPD² combines ADC technology to deliver protein degraders selectively to cancer cells, minimizing off-target effects and enhancing therapeutic efficacy.

Number of Employees

21people

Average Salary

174.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 25.444.0Point

PBR

7.92Industry Average 1.260.0Point

6.3x industry avg (risky)

ROE

-33.22Industry Average -6.033.5Point

5.5x industry avg (excellent)

Debt Ratio

17.44Industry Average 6.620.0Point

2.6x industry avg (risky)

Trend 2024~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼99.9% (1-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼521.0% (1-year basis)

ROE Trend

0.0 / 4

Detailed News Sentiment

5 totalPositive 3Neutral 2Negative 0Average Sentiment Score 67

Neutral
[단독]중소 제약기업 62% “AI 기업과 협업, 공동 R&D 가장 선...
AI 기술 활용에 대한 중소 제약바이오 기업들의 어려움이 언급되나, 오름테라퓨틱의 직접적인 영향은 명시되지 않음.
Positive
‘적자’ 오름테라퓨틱, 첫 개발 마일스톤 가시권…연내 유입 여부 촉.....
오름테라퓨틱의 핵심 파이프라인 ORM-6151이 임상 확대를 통해 연내 기술료 수령 가능성이 높아져 긍정적 전망.
Positive
박셀바이오, 첨생법 제도 개편 최대 수혜…오름, 中 '빅딜' 기대감[바...
오름테라퓨틱은 첨생법 제도 개편으로 인해 중국 대형 딜 기대감이 높아져 긍정적인 시장 반응을 받고 있다.

Detailed Momentum

52-week position3.0Point

52w lower range (21%)

Current 47,700Won52-week high 143,70052-week low 20,750

1-month return0.0Point

1m -17.33% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral기업설명회(IR)개최2026-07-06
Neutral기업설명회(IR)개최2026-06-29
Neutral주식매수선택권부여에관한신고2026-06-29
Neutral[기재정정]기업설명회(IR)개최2026-06-29